← 483 OBSERVATION EXPLORER

FDA 483 OBSERVATION · #882 OF 1,000 MOST-CITED

Cleaning SOP/inspection

FDA cited this observation 16 times across 16 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

BY PROGRAM AREA
Drugs16
BY FISCAL YEAR
FY20251
FY20243
FY20233
FY20212
FY20202
FY20192
FY20183

How FDA worded it — real examples

Procedures for the cleaning and maintenance of equipment are deficient regarding inspection of the equipment for cleanliness immediately before use.

Alembic Pharmaceuticals Limited · Vadodara · Drugs · 2024-11-22

Procedures for the cleaning and maintenance of equipment are deficient regarding inspection of the equipment for cleanliness immediately before use.

Padagis US LLC · Minneapolis, Minnesota · Drugs · 2024-09-06

Procedures for the cleaning and maintenance of equipment are deficient regarding inspection of the equipment for cleanliness immediately before use.

Amorepacific Corporation · Osan · Drugs · 2024-03-16

Procedures for the cleaning and maintenance of equipment are deficient regarding inspection of the equipment for cleanliness immediately before use.

GlaxoSmithKline Biologicals · Saint-Amand-Les-Eaux · Drugs · 2024-03-12

Procedures for the cleaning and maintenance of equipment are deficient regarding inspection of the equipment for cleanliness immediately before use.

Teva Pharmaceutical Industries Ltd. · Kfar Saba · Drugs · 2023-05-23

Procedures for the cleaning and maintenance of equipment are deficient regarding inspection of the equipment for cleanliness immediately before use.

Vertex Pharmaceuticals Incorporated · Boston, Massachusetts · Drugs · 2023-05-04

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Cleaning validationPharma industry

Examples are a representative sample of FDA's published inspection observations. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →